Company intelligence / Profile preview

Bio 54

Raleigh, North Carolina, United Statesmarypoffenroth.com ↗

Ownership: Private
Development stage: Other

Overview

Bio 54 has advanced its lead candidate BXP-154, a small molecule drug for the treatment of hemorrhage, into Phase 2 clinical trials. One completed randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of BXP154B (Tranexamic Acid Sterile Topical Solution) for external bleeding from minor wounds in subjects on apixaban. No detailed results are publicly available.

Therapeutic areas: Hematology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

BXP-154

Beyond the preview

Go deeper on Bio 54.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bio 54.

Explore the full profile